Exparel: Additional Phase IV data

Additional data from the open-label Phase IV IMPROVE trial in 39 patients undergoing open colectomy laparoscopic colectomy or ileostomy reversal surgical procedures showed that an Exparel-based multi-modal regimen led to significant reductions on the co-primary endpoints of mean total amount of opioid consumption (57 vs. 115 mg, p=0.025) and average cost of hospitalization ($8,766 vs. $11,850, p=0.027) vs. standard opioid-based postsurgical treatment regimen. The Exparel regimen also significantly reduced the co-primary endpoint of median length of hospital stay vs. standard opioid-based regimen (2 vs. 4.9 days, p=0.004). The multi-modal regimen consisted of intraoperative infiltration of 266 mg Exparel to the surgical site after surgery followed by IV or oral acetaminophen and ibuprofen. Standard therapy included IV morphine or hydromorphone delivered via a patient-controlled analgesia device and opioid-based rescue medication. All patients were offered rescue medication with IV opioids or oral opioids plus acetaminophen. ...